Filtered By:
Source: American Heart Journal
Condition: Heart Disease
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 47 results found since Jan 2013.
Improving outcomes in patients with atrial fibrillation: Rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial
Conclusion EAST will determine whether rhythm control therapy, when applied early after the initial diagnosis of AF, can prevent cardiovascular complications associated with AF.
Source: American Heart Journal - October 20, 2014 Category: Cardiology Source Type: research
Parathyroid hormone concentration and risk of cardiovascular diseases: The Atherosclerosis Risk in Communities (ARIC) study
Conclusions: This large prospective study failed to support the hypothesis that elevated PTH is an independent risk marker for incident CVD. When our data were added to the previous meta-analysis, the pooled hazard ratio remained statistically significant but weakened.
Source: American Heart Journal - June 11, 2014 Category: Cardiology Authors: Aaron R. Folsom, Alvaro Alonso, Jeffrey R. Misialek, Erin D. Michos, Elizabeth Selvin, John H. Eckfeldt, Josef Coresh, James S. Pankow, Pamela L. Lutsey Tags: Coronary Artery Disease Source Type: research
Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: Final baseline characteristics of the IMPROVE-IT study population
Background: The IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) is evaluating the potential benefit for reduction in major cardiovascular (CV) events from the addition of ezetimibe versus placebo to 40 mg/d of simvastatin therapy in patients who present with acute coronary syndromes and have low-density lipoprotein cholesterol (LDL-C) ≤125 mg/dL.Methods: The primary composite end point is CV death, nonfatal myocardial infarction (MI), nonfatal stroke, rehospitalization for unstable angina (UA), and coronary revascularization (≥30 days postrandomization). The simvastatin monotherapy arm’s LDL-C target is
Source: American Heart Journal - May 19, 2014 Category: Cardiology Authors: Michael A. Blazing, Robert P. Giugliano, Christopher P. Cannon, Thomas A. Musliner, Andrew M. Tershakovec, Jennifer A. White, Craig Reist, Amy McCagg, Eugene Braunwald, Robert M. Califf Tags: Acute Ischemic Heart Disease Source Type: research
Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial
Background: Extensive coronary artery disease (CAD) is associated with higher risk. In this substudy of the PLATO trial, we examined the effects of randomized treatment on outcome events and safety in relation to the extent of CAD.Methods: Patients were classified according to presence of extensive CAD (defined as 3-vessel disease, left main disease, or prior coronary artery bypass graft surgery). The trial's primary and secondary end points were compared using Cox proportional hazards regression.Results: Among 15,388 study patients for whom the extent of CAD was known, 4,646 (30%) had extensive CAD. Patients with extensiv...
Source: American Heart Journal - April 14, 2014 Category: Cardiology Authors: Anna Kotsia, Emmanouil S. Brilakis, Claes Held, Christopher Cannon, Gabriel P. Steg, Bernhard Meier, Frank Cools, Marc J. Claeys, Jan H. Cornel, Philip Aylward, Basil S. Lewis, Douglas Weaver, Gunnar Brandrup-Wognsen, Susanna R. Stevens, Anders Himmelmann Tags: Acute Ischemic Heart Disease Source Type: research
Prognosis of elderly patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention in 2001 to 2011: A report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) registry
Conclusions: The prognosis of patients older than 80 years treated with primary PCI for STEMI was relatively unchanged during the 10-year inclusion period, despite changes in patient characteristics and treatment. Advanced age increased the risk of adverse events, but survivors of the early phase after PCI had a slightly improved prognosis compared with the general population.
Source: American Heart Journal - February 27, 2014 Category: Cardiology Authors: Matthijs A. Velders, Stefan K. James, Berglind Libungan, Giovanna Sarno, Ole Fröbert, Jörg Carlsson, Martin J. Schalij, Per Albertsson, Bo Lagerqvist Tags: Acute Ischemic Heart Disease Source Type: research
Growth differentiation factor 15 and cardiovascular events in patients with stable ischemic heart disease (The Heart and Soul Study)
Background: Growth differentiation factor 15 (GDF-15) is a relatively new biomarker that predicts mortality in patients with chronic stable angina or acute coronary syndrome. However, the association of GDF-15 with cardiovascular (CV) events and the mechanisms of this association are not well understood.Methods: We measured plasma GDF-15 and cardiac disease severity in 984 patients with stable ischemic heart disease who were recruited for the Heart and Soul Study between September 2000 and December 2002. Subsequent CV events (myocardial infarction, stroke, and CV death), hospitalization for heart failure, and all-cause mor...
Source: American Heart Journal - December 9, 2013 Category: Cardiology Authors: David W. Schopfer, Ivy A. Ku, Mathilda Regan, Mary A. Whooley Tags: Coronary Artery Disease Source Type: research
Association of all-cause and cardiovascular mortality with prehypertension: A meta-analysis
Background: Studies of prehypertension and mortality are controversial after adjusting for other cardiovascular risk factors. This meta-analysis sought to evaluate the association of prehypertension with all-cause and cardiovascular disease (CVD) mortality.Methods: The PubMed, EMBASE, Cochrane Library databases, and conference proceedings were searched for studies with data on prehypertension and mortality. The relative risks (RRs) of all-cause, CVD, coronary heart disease (CHD), and stroke mortality were calculated and presented with 95% CIs. Subgroup analyses were conducted according to blood pressure, age, gender, ethni...
Source: American Heart Journal - November 8, 2013 Category: Cardiology Authors: Yuli Huang, Liang Su, Xiaoyan Cai, Weiyi Mai, Sheng Wang, Yunzhao Hu, Yanxian Wu, Hongfeng Tang, Dingli Xu Tags: Hypertension Source Type: research
Balloon aortic valvuloplasty in the era of transcatheter aortic valve replacement: Acute and long-term outcomes
Background: The use of balloon aortic valvuloplasty (BAV) has resurged since the development of transcatheter aortic valve replacement (TAVR). The aim of our study was to determine the procedural and long-term outcomes of patients treated by BAV in the early TAVR era.Methods: From 2005 to 2008, 323 consecutive patients presenting with severe aortic stenosis were treated by BAV in our institution.Results: Mean age and logistic EuroSCORE were 80.5 ± 9.9 years and 28.7% ± 12.5%, respectively. The effective orifice area increased from 0.68 ± 0.25 to 1.12 ± 0.39 cm2 (P
Source: American Heart Journal - November 6, 2013 Category: Cardiology Authors: Hélène Eltchaninoff, Eric Durand, Bogdan Borz, Akira Furuta, Karim Bejar, Alexandre Canville, Ali Farhat, Chiara Fraccaro, Matthieu Godin, Christophe Tron, Rahul Sakhuja, Alain Cribier Tags: Valvular and Congenital Heart Disease Source Type: research
Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial
Conclusions: LEADER commenced in September 2010, and enrollment concluded in April 2012. There were 9,340 patients enrolled at 410 sites in 32 countries. The mean age of patients was 64.3 ± 7.2 years, 64.3% were men, and mean body mass index was 32.5 ± 6.3 kg/m2. There were 7,592 (81.3%) patients with prior CVD and 1,748 (18.7%) who were high risk but without prior CVD. It is expected that LEADER will provide conclusive data regarding the cardiovascular safety of liraglutide relative to the current standard of usual care for a global population of patients with T2DM.
Source: American Heart Journal - October 4, 2013 Category: Cardiology Authors: Steven P. Marso, Neil R. Poulter, Steven E. Nissen, Michael A. Nauck, Bernard Zinman, Gilbert H. Daniels, Stuart Pocock, William M. Steinberg, Richard M. Bergenstal, Johannes F.E. Mann, Lasse Steen Ravn, Kirstine Brown Frandsen, Alan C. Moses, John B. Bus Tags: Trial Design Source Type: research
Improving outcomes in patients with atrial fibrillation: Rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial
Conclusion: EAST will determine whether rhythm control therapy, when applied early after the initial diagnosis of AF, can prevent cardiovascular complications associated with AF.
Source: American Heart Journal - August 1, 2013 Category: Cardiology Authors: Paulus Kirchhof, Günter Breithardt, A. John Camm, Harry J. Crijns, Karl-Heinz Kuck, Panos Vardas, Karl Wegscheider Tags: Trial Design Source Type: research
Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: Insights from the PLATelet inhibition and patient outcomes (PLATO) trial
Conclusions: Prior-CABG patients presenting with acute coronary syndrome are a high-risk cohort for death and recurrent cardiovascular events but have a lower risk for major bleeding. Similar to the results in no-prior-CABG patients, ticagrelor was associated with a reduction in ischemic events without an increase in major bleeding.
Source: American Heart Journal - July 29, 2013 Category: Cardiology Authors: Emmanouil S. Brilakis, Claes Held, Bernhard Meier, Frank Cools, Marc J. Claeys, Jan H. Cornel, Philip Aylward, Basil S. Lewis, Douglas Weaver, Gunnar Brandrup-Wognsen, Susanna R. Stevens, Anders Himmelmann, Lars Wallentin, Stefan K. James Tags: Acute Ischemic Heart Disease Source Type: research
Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease
Background: The impact of nonpersistence on events and of events on persistence is unclear. We studied the effects of nonpersistence on outcomes and events on nonadherence in a randomized placebo controlled trial in 40 countries on 25,620 patients.Methods: In the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET), persistent patients (n = 20,991) were compared with individuals who had permanently stopped study medications (n = 4,629).Results: Older age, female gender, less physical activity, less education, and history of stroke/transient ischemic attack, depression, and diabetes we...
Source: American Heart Journal - June 26, 2013 Category: Cardiology Authors: Michael Böhm, Helmut Schumacher, Ulrich Laufs, Peter Sleight, Roland Schmieder, Thomas Unger, Koon Teo, Salim Yusuf Tags: Acute Ischemic Heart Disease Source Type: research
Sex differences in clinical outcomes in patients with stable angina and no obstructive coronary artery disease
Conclusions: Women with stable angina and nonobstructive CAD are 3 times more likely to experience a cardiac event within the first year of cardiac catheterization than men. A prospective trial to examine the impact of medical therapy on MACE in patients with nonobstructive CAD is warranted.
Source: American Heart Journal - May 1, 2013 Category: Cardiology Authors: Tara L. Sedlak, May Lee, Mona Izadnegahdar, C. Noel Bairey Merz, Min Gao, Karin H. Humphries Tags: Acute Ischemic Heart Disease Source Type: research
